Taken together, the patients with CRC and high risk scores were more sensitive to doxorubicin, imatinib, JNK inhibitor VIII, nilotinib, pazopanib, and thapsigargin than low risk patients. This evidence concerns the gene MAPK8 and colorectal carcinoma.